HT-1376人膀胱癌细胞

HT1376/HT1376细胞系/HT1376细胞株/HT1376人膀胱癌细胞

Cell line name HT-1376

Synonyms HT1376; HT 1376; HT 1376.T

Accession CVCL_1292

Resource Identification Initiative To cite this cell line use: HT-1376 (RRID:CVCL_1292)

Comments Part of: BLA-40 bladder carcinoma cell line panel.

Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Part of: COSMIC cell lines project.

Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).

Part of: UBC-40 urothelial bladder cancer cell line index.

Population: Caucasian.

Doubling time: 31 hours (PubMed=3708594); 31 hours (PubMed=26055179); ~60 hours (DSMZ=ACC-397).

Microsatellite instability: Stable (MSS) (Sanger).

Omics: Array-based CGH.

Omics: CNV analysis.

Omics: Deep exome analysis.

Omics: Deep quantitative proteome analysis.

Omics: DNA methylation analysis.

Omics: SNP array analysis.

Omics: Transcriptome analysis by microarray.

Omics: Transcriptome analysis by RNAseq.

Misspelling: HT-137; ChEMBL-Targets=CHEMBL614664; ChEMBL-Cells=CHEMBL3308610.

Misspelling: HT-1367; PubMed=29732388.

Derived from site: In situ; Urinary bladder; UBERON=UBERON_0001255.

PubMed=8873383; DOI=10.1007/BF00295899

Stadler W.M., Olopade O.I.

The 9p21 region in bladder cancer cell lines: large homozygous deletion inactivate the CDKN2, CDKN2B and MTAP genes.

Urol. Res. 24:239-244(1996)

 

PubMed=9850064

Markl I.D.C., Jones P.A.

Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer.

Cancer Res. 58:5348-5353(1998)

 

PubMed=11416159; DOI=10.1073/pnas.121616198; PMCID=PMC35459

Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G., Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R., Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.

Short tandem repeat profiling provides an international reference standard for human cell lines.

Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001)

 

PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113

Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

 

PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662

Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Cancer Res. 70:2158-2164(2010)

 

PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027

Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Nature 483:603-607(2012)

 

PubMed=23401075; DOI=10.1002/path.4176

Guo Y.-N., Chekaluk Y., Zhang J.-M., Du J.-Y., Gray N.S., Wu C.-L., Kwiatkowski D.J.

TSC1 involvement in bladder cancer: diverse effects and therapeutic implications.

J. Pathol. 230:17-27(2013)

 

PubMed=24367658; DOI=10.1371/journal.pone.0084411; PMCID=PMC3867501

Ross R.L., Burns J.E., Taylor C.F., Mellor P., Anderson D.H., Knowles M.A.

Identification of mutations in distinct regions of p85 alpha in urothelial cancer.

PLoS ONE 8:E84411-E84411(2013)

 

PubMed=24035680; DOI=10.1016/j.eururo.2013.08.057

Hurst C.D., Platt F.M., Knowles M.A.

Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine.

Eur. Urol. 65:367-369(2014)

 

PubMed=24459064; DOI=10.1007/s13277-013-1604-3

Pinto-Leite R., Carreira I.M., Melo J.B., Ferreira S.I., Ribeiro I.P., Ferreira J., Filipe M., Bernardo C., Arantes-Rodrigues R., Oliveira P., Santos L.

Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Tumor Biol. 35:4599-4617(2014)